Kidney Health Discussion, Boldenone Making A Comeback? High-Dose SLU-PP-332 & Bioglutide Updates

Key wellness & kidney-health strategies mentioned

1) Prioritize kidney protection (prevention > treatment)

• Manage blood pressure as the top priority to reduce long-term damage to the kidney’s delicate filtering structures (glomular tissues).
• Control oxidative stress, described as an early driver of kidney harm.

2) Optimize oxidative stress / antioxidant support

The discussion covered antioxidants and oxidative-stress–lowering approaches as potentially protective for nephron structures. Examples mentioned (not as a guaranteed protocol, but as options) included:

• Glutathione / NAC (supporting glutathione availability)
• Cordyceps mushroom
• Astragalus (mentioned for creatinine-related effects)
• Methylene blue (with a caveat that it can interact with nitric oxide at higher doses)
• Vitamin C / vitamin E / “royal jelly” (mentioned as potentially mitigating oxidative-stress injury)

3) Interpret kidney markers more intelligently

• Creatinine alone isn’t enough, since training intensity, hydration, protein intake, and creatine supplementation can raise creatinine.
• Ways to reduce misleading readings when assessing kidney filtration:
  • Avoid creatine for ~2 weeks before testing (if trying to get a clearer signal)
  • Lower protein intake to around ~1 g per pound body weight
  • Rest ~4 days prior to the blood draw
• Use multiple kidney markers/calculations, such as:
  • Cystatin C
  • eGFR
  • Additional markers like ADMA (for oxidative/nitric-oxide–related stress)

4) Suggested self-checks for kidney risk (home + clinician)

• Urine protein screening strips
  • Emphasized for cost-effective daily/regular monitoring.
  • Albumin-to-creatinine ratio (ACR) was discussed as more informative than simple dipsticks.
• 24-hour urine collection
  • Suggested 1–2x per year—cumbersome, but provides better GFR insight.
• Ultrasound
  • Recommended at intervals for prevention (noninvasive; can show structural changes).
  • Caveat: it may show false positives due to surrounding muscle inflammation.

5) Treat urine protein “signals” seriously—especially albumin/protein levels

• Framed as guidance:
  • Mild protein leakage may be manageable, but worsening proteinuria (e.g., +1 progressing upward or higher albumin/protein levels) is a reason to act.
• Key point:
  • If proteinuria reflects leakage, repair is harder once damage is advanced, so the goal becomes preserving function and stopping further harm.

6) Creatine + high-intensity training: watch context, not just numbers

• Bodybuilders were warned that creatinine changes can reflect metabolism/muscle breakdown, not necessarily true kidney damage.
• Mentioned:
  • If creatinine rises during a cycle but returns toward baseline after variables change, it may be a “sanity check,” not proof that no damage occurred.
• Trend monitoring can matter more than any single value.

7) Single-kidney caution (personal account)

One presenter described living with unilateral renal agenesis and improved eGFR after:

• Stopping alcohol
• Returning to training
• Cleaner diet
• Testosterone and growth hormone (presented as major contributors in their case)

Strong warning:

• Underground-lab growth hormone may differ due to fillers/quality issues and may not produce the same benefit.

---

Productivity / lifestyle wellness themes (behavioral habits)

1) Dieting psychology and “pressure” management

• The discussion included reducing mental pressure after injuries or life events.
• The “muscle dysmorphia / shred-illusion” effect was described (feeling “fat” even when visibly lean).
• Reassurance approach:
  • Ask a partner for a direct “do I look good enough?” reality check.

2) Consistency over extremes

• Emphasized that atrophy can accelerate quickly after stopping training (supported by anecdotal examples and a cited study showing tissue loss after ~10 days off).
• Training frequency discussed:
  • “Frequency matters more than volume,” and overly spaced schedules may work poorly for natural growth (in principle).

---

Productivity / performance strategies (fitness)

1) Training structure: reduce atrophy and cycling losses

• Avoid long gaps in training to prevent rapid deconditioning.

2) Exercise mimetics skepticism (medication vs actual exercise)

• A paper was discussed arguing exercise-mimetic pills aren’t equivalent to exercise.
• Core takeaway:
  • Use supplements/meds only as adjuncts, not replacements.
  • Exercise triggers broader hormonal/vascular/neurological responses that single compounds may not replicate.

---

Medication/compound caution points raised (especially for kidney safety)

1) GLP-1s: acknowledge benefits + uncertainty/risks

• Noted:
  • Long-term safety is not definitively known (“rushed to market” concern).
  • Side effects and mood/anxiety/depression reports were discussed.
• Lifestyle anchor:
  • Better diet and fiber were framed as the more “natural” foundation for GLP-related gut benefits.

2) Diuretics around competition: major kidney & cardiovascular risk

Strong warnings against:

• Heavy diuretic protocols for multiple days close to shows.
• Water restriction + electrolyte mismanagement, leading to rebound issues.

Alternative mentioned for a “dry look”:

• Telmisartan + bloflav/en (described as similar to eplerenone/“emplosin”-type approaches rather than aggressive loop diuretics)
  • Suggested as potentially more favorable for sodium/potassium handling and less rebound.

Severe consequences were described anecdotally:

• Post-show fluid retention/rebound leading to dangerous outcomes, including heart failure events.

3) Growth hormone “loading/unloading” (competitive context)

Protocol concept discussed:

• Remove GH earlier to improve conditioning sharpness.
• Then reintroduce near/just before show to restore fullness.
• Follow with careful post-show balancing (water/sodium management; sometimes anti-mineralocorticoid support).

Framed as:

• A competitive/elite strategy with individual variability and risk.

---

Presenters / sources listed in the subtitles

• Dr. Dean St. Mart (presenter; referenced as “doctor”)
• Kurt Havens (presenter)
• Steve (presenter; often addressed directly)
• AJ (mentioned in relation to a project/content collaboration; not fully described)
• Sources mentioned indirectly via studies/papers/examples (no specific article titles provided in subtitles):
  • “Exercise mimetic” studies involving terms like icar/dicar (unclear transcription), cardarine, metformin, and animal model comparisons
  • Kidney-related discussions referencing: FSGS, eGFR, cystatin C, ADMA, ACR, 24-hour urine, ultrasound
  • “EQ” (boldenone) toxicity literature, including animal + retrospective human context